• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1266604 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type* t7 r& x) f6 e' l0 L
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
9 L8 b* a1 R0 b* z+ Author Affiliations3 d# i$ l% Z6 {/ T! h! \
% J* q/ u% J( x' P/ r$ g' u
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
2 M3 u1 E5 H7 H& f. ?$ `" |2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
+ K+ U# v7 J- i" C  [$ y. u3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
" E+ X5 G" c) x) a, X4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan % P7 A! B0 B6 |% l5 e1 C6 h
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan & o7 F) _$ b4 s+ }
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan ' d* d* h) g& W) f7 T
7Kinki University School of Medicine, Osaka 589-8511, Japan
6 m- k9 z  D' b/ g8Izumi Municipal Hospital, Osaka 594-0071, Japan
) i9 K, @$ @" @' i. Q! j9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan # w8 \1 o1 H. V/ Q* C0 B/ @
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
6 a" }8 K/ V4 z1 lAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
& D5 B# {, P, F/ P5 t" \
: w& y1 f+ a# R# i. r$ O
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type 6 ^( `9 h' m! z. S+ D4 j" B

2 _7 L/ v% i- M1 QAuthors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato
3 `$ a7 K8 Q: c  P& v8 I& F7 b( ?6 R/ e, n+ K9 w. Z) J# z' H1 E
Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  9 l- g6 \! J6 y" c# D( @. d

2 [: a9 e1 {% {Published online on: Thursday, December 1, 2011 : I7 k4 r" g! R: `( \$ V* K
5 ^- C* J" }; i* }
Doi: 10.3892/ol.2011.507 6 J# a' [8 h0 u" v

5 ?; Z& Z" N8 V- N; U5 x7 g( yPages: 405-410   {) [7 @# a3 M$ ^5 p! O' I! l7 Q
" j$ h' P5 M% O
Abstract:; _% {: H  ]5 K3 V1 x
S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.1 }* i' @7 V+ X  p# A; B" d

* u- k3 \1 L& @7 ^- A# @) h4 J
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
6 }, G$ L, M8 l5 ]1 IF. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3 # Z$ F+ A! }6 b7 C- w, C3 h- E2 i2 E
+ Author Affiliations8 Z5 d- @5 x9 o
1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu
" h5 m# v0 y/ S5 H% o2Department of Thoracic Surgery, Kyoto University, Kyoto 8 p- _) l# E2 J3 S: K9 j$ M. y, J
3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan 1 ]8 f- M: u. S) n, m9 g$ H" c6 r
&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp 3 ^$ N! w# Z! K, i& K: F! q. M& N
Received September 3, 2010. ) X6 D9 Q" M, P7 q: ?+ }+ h
Revision received November 11, 2010.
  n/ R& z! f% [* K7 NAccepted November 17, 2010.
* V5 @8 K0 O  B! }( K% E4 OAbstract% P) P1 |3 k# u) i7 i5 d
Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed. 8 W3 M  p3 H, C
Patients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes. , K- U* _! r! u* u  G
Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression. ; U( i  _. M0 \, W3 }$ C4 j/ v
Conclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study.   f: N7 R) c& D2 u9 Z. k
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。" x+ l! ]9 D* G) m
今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?
: M2 g: w  C9 M9 c9 c1 @- ?
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy6 b. j% C$ j& Y7 D& l
http://clinicaltrials.gov/ct2/show/NCT01523587
* r! o2 W0 r8 M0 s! d0 p
7 c% V# Z* A  ]% t; o% yBIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
% d! p+ e) D9 W6 x$ E6 {! phttp://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑 0 K; P! z# a& I1 D5 a, ?/ k
2 p# Y; ?0 h  p* o0 A7 \- s5 q! o
从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。* {2 B) C: {* U* v2 `2 w( ~6 [, a
至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
1 y1 ?6 ?! B% p$ `5 @6 h
没有副作用是第一追求,效果显著是第二追求。* E0 ^' y. Z/ s! W
不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表